155 related articles for article (PubMed ID: 38792635)
1. Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence.
Sansone P; Giaccari LG; Di Flumeri G; Pace MC; Pota V; Coppolino F; Brunetti S; Aurilio C
Life (Basel); 2024 May; 14(5):. PubMed ID: 38792635
[TBL] [Abstract][Full Text] [Related]
2. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
Mansour H; Ouweini AEL; Chahine EB; Karaoui LR
Am J Health Syst Pharm; 2021 Mar; 78(8):674-683. PubMed ID: 33580649
[TBL] [Abstract][Full Text] [Related]
3. Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.
Smith JR; Rybak JM; Claeys KC
Pharmacotherapy; 2020 Apr; 40(4):343-356. PubMed ID: 32060929
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections.
Kaye KS; Boucher HW; Brown ML; Aggrey A; Khan I; Joeng HK; Tipping RW; Du J; Young K; Butterton JR; Paschke A
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094127
[TBL] [Abstract][Full Text] [Related]
5. Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
Heo YA
Drugs; 2021 Feb; 81(3):377-388. PubMed ID: 33630278
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study.
Kohno S; Bando H; Yoneyama F; Kikukawa H; Kawahara K; Shirakawa M; Aoyama N; Brown M; Paschke A; Takase A
J Infect Chemother; 2021 Feb; 27(2):262-270. PubMed ID: 33191112
[TBL] [Abstract][Full Text] [Related]
7. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
Lucasti C; Vasile L; Sandesc D; Venskutonis D; McLeroth P; Lala M; Rizk ML; Brown ML; Losada MC; Pedley A; Kartsonis NA; Paschke A
Antimicrob Agents Chemother; 2016 Oct; 60(10):6234-43. PubMed ID: 27503659
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Titov I; Wunderink RG; Roquilly A; Rodríguez Gonzalez D; David-Wang A; Boucher HW; Kaye KS; Losada MC; Du J; Tipping R; Rizk ML; Patel M; Brown ML; Young K; Kartsonis NA; Butterton JR; Paschke A; Chen LF
Clin Infect Dis; 2021 Dec; 73(11):e4539-e4548. PubMed ID: 32785589
[TBL] [Abstract][Full Text] [Related]
9. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms.
Yang J; Naik J; Massello M; Ralph L; Dillon RJ
Infect Dis Ther; 2022 Aug; 11(4):1443-1457. PubMed ID: 35334080
[TBL] [Abstract][Full Text] [Related]
11. Imipenem/cilastatin sodium/relebactam fixed combination to treat urinary infections and complicated intra-abdominal bacterial infections.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2020 Apr; 56(4):241-255. PubMed ID: 32309820
[TBL] [Abstract][Full Text] [Related]
12. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.
Motsch J; Murta de Oliveira C; Stus V; Köksal I; Lyulko O; Boucher HW; Kaye KS; File TM; Brown ML; Khan I; Du J; Joeng HK; Tipping RW; Aggrey A; Young K; Kartsonis NA; Butterton JR; Paschke A
Clin Infect Dis; 2020 Apr; 70(9):1799-1808. PubMed ID: 31400759
[TBL] [Abstract][Full Text] [Related]
13. In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.
Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
Int J Antimicrob Agents; 2020 Jan; 55(1):105841. PubMed ID: 31704217
[TBL] [Abstract][Full Text] [Related]
14.
Powles MA; Galgoci A; Misura A; Colwell L; Dingley KH; Tang W; Wu J; Blizzard T; Motyl M; Young K
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866878
[TBL] [Abstract][Full Text] [Related]
15. New evidence in severe pneumonia: imipenem/ cilastatin/relebactam.
Girón RM; Ibáñez A; Gómez-Punter RM; Alarcón T
Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):46-49. PubMed ID: 35488826
[TBL] [Abstract][Full Text] [Related]
16. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: imipenem-cilastatin/relebactam results from randomized controlled trials.
Yang Q; Yang Y; He R; Yu B; Zhong Y; Lin F
Front Med (Lausanne); 2023; 10():1304369. PubMed ID: 38188339
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital-acquired/ventilator-associated bacterial pneumonia.
Patel M; Bellanti F; Daryani NM; Noormohamed N; Hilbert DW; Young K; Kulkarni P; Copalu W; Gheyas F; Rizk ML
Clin Transl Sci; 2022 Feb; 15(2):396-408. PubMed ID: 34704389
[TBL] [Abstract][Full Text] [Related]
19. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
[TBL] [Abstract][Full Text] [Related]
20. An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date.
Sellarès-Nadal J; Eremiev S; Burgos J; Almirante B
Expert Opin Pharmacother; 2021 Aug; 22(12):1521-1531. PubMed ID: 34120547
[No Abstract] [Full Text] [Related]
[Next] [New Search]